PEAH – Policies for Equitable Access to Health

A project run by Daniele Dionisio

PEAH will be closed 26 June-7 July for summer holidays

  PEAH

@PEAH

Dear Friends and Readers,
 
I am pleased to announce that our GESPAM Project just became a new domain, independent platform incisively renamed 

 PEAH – Policies for Equitable Access to Health

These changes will allow the Project to gain more freedom and appeal while aligning in full with the overall GESPAM scope and framework. 
As such, in the wake of GESPAM success, PEAH keeps focussing on the best options for use of trade and government rules related to public health in resource-limited countries. 
Its analysis includes:
-the effects of current trade agreements and intellectual property (IP) standards on access to health services and appropriate, high-quality medicines. 
-the opportunities offered by new financing mechanisms and innovation models for fair access to care, food and treatments and the development of medicines for diseases that disproportionately affect the developing countries.

-reliable ways for better coherence and collaboration among stakeholders supposed to streamline access to health priorities.

These questions are to the point now that the impact of governments’ policies on public health and access to appropriate, affordable, high-quality medicines is an issue of global concern in the international agenda.

And this occurs at a time when more than half of a total population of 5 billion people in developing countries rely on less than $2 per day, counterfeit/substandard drugs are booming, and key medicines are under prolonged patent regimes which are further exacerbated by free trade agreements and governments’ choices turning IP agendas into policies which protect monopolistic interests at the expense of unbiased access to lifesaving medicines. 

One thought on “”

  1. I am a Cameroonian. For the past ten years I have been involved in the care of children living with diabetes in Yaoundé Cameroon. “Changing Diabetes in Children” program has been very important for us: creation of childhood diabetes clinics within government hospitals, training of health care personnel, early diagnosis and free diabetes care offer to children living with diabetes in Cameroon. This program is suppose to end in December this year and we are trying to sustained it. We are hoping more involvement from the ministry of health; continue insulin supply from Novo Nordisk, glucometers and strips from Roche; involving other partners for education.
    I was really surprise by the paper written by Rebecca Barlow-Noone. She wrote:
    ” Novo Nordisk’s ‘Changing Diabetes’ Aid Programme Exacerbates Issues of Insulin Access, and Must End for Compulsory Licensing to be Effective”.
    Who is Rebecca B-L?
    Looking at the biography, she is not Cameroonian, she has never been in Cameroon nor in other African countries. She is not involved in any diabetic support program in Cameroon or Africa. She is not supporting in children living with diabetes in Cameroon. She has no experience about drugs safety, drug licensing.
    How is this lady aware of the problem in Cameroon? What interest?
    How can she give a point of view in blog without discussing with the patients benefiting from the intervention, the parents, patient association, responsible of the Ministry of health in Cameroon and also local responsible of the project?
    How can a person asked for an immediate arrest of an intervention who has contributed to reduction of mortality of children from 80% to 10%? What solutions for children?
    Is this lady happy to see our children dying massively because of lack of diagnosis and care?
    Something is wrong about this lady. I don’t believe she is mad or a bad person.
    SHE SHOULD DECLARE HER CONFLICT OF INTEREST
    I hope that the administrator of this blog will give us opportunity to react to such a misconduct and give the truth about the CDiC project in Cameroon and also about insulin issue. It is more complicated and cannot be solve in a blog.
    Best regards.

Leave a Reply

Your email address will not be published. Required fields are marked *